<DOC>
	<DOCNO>NCT02171624</DOCNO>
	<brief_summary>Open-label , two-way crossover design quinidine sulfate run-in period follow randomised sequence dabigatran etexilate plus quinidine sulfate dabigatran etexilate alone evaluate safety co-administration dabigatran etexilate quinidine . pharmacokinetic interaction quinidine dabigatran etexilate .</brief_summary>
	<brief_title>Safety Pharmacokinetics Quinidine Alone Combination With Dabigatran Etexilate</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Healthy male female subject Age ≥18 Age ≤55 year Body Mass Index ( BMI ) ≥18.5 BMI &lt; 30 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation . Any finding medical examination ( include Blood Pressure ( BP ) , Pulse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within thirty day prior administration trial Inability refrain smoke trial day Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Taking drug know Pgp and/or CYP3A4 inhibitor inducer ( verapamil , phenothiazine antipsychotic , macrolide antibiotic ( clarithromycin , erythromycin ) , antifungal drug , antiviral drug ( protease inhibitor like nelfinavir ) St. John´s Wort ) within last 4 week screen Taking drug know CYP2D6 substrate ( antidepressant , antiarrhythmic , beta blocker ) within last 2 week screen For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception e.g. , sterilisation , IUD ( intrauterine device ) , use barrier method contraception least 3 month prior participation study Are willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Chronic use oral contraception hormone replacement contain ethinyl estradiol method contraception Partner unwilling use condom Currently lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>